TAGAMET
CIMETIDINE
Approval overview TAGAMET is listed in Drugs@FDA under application 017920 (NDA).
Review priority: PRIORITY Marketing status: Discontinued Active ingredient CIMETIDINE Form and strength TABLET;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor GLAXOSMITHKLINE Submission history Latest submission status date: 2006-07-12 00:00:00.
Structured Monograph
Clinical summary
Approval overview TAGAMET is listed in Drugs@FDA under application 017920 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient CIMETIDINE Form and strength TABLET;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor GLAXOSMITHKLINE Submission history Latest submission status date: 2006-07-12 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.